Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics (LUCD) confirmed its first LBM win with Concert, which covers 10M lives. Analyst Mark Massaro maintained a Buy rating and $2.50 price target, citing strong clinical evidence for its EsoGuard test. Q2 revenue grew 27% YoY to $1.5M, with a loss of 8 cents per share. The company awaits CMS coverage for EsoGuard, with management expressing confidence in a positive draft LCD.
How this was made
The 30-second read
Why it matters
The earnings release and contract win provide fresh positive catalysts, though Medicare coverage timing remains uncertain.
Market read
Earnings and contract news could drive short‑term price movement for LUCD and influence sentiment in the niche diagnostics sector.
What to watch
Potential delays in CMS LCD approval and reliance on a single large LBM partner.
Background
Lucid Diagnostics reported Q2 results with 27% revenue growth and a loss of $0.08 per share, highlighted a new LBM contract with Concert and an analyst upgrade.
Ticker impact
Q2 earnings disclosed revenue growth, loss per share, and a new LBM contract win, plus an analyst upgrade with a $2.50 price target.
Potential upside of 10‑15% if the market prices in the contract win and analyst upgrade.
Earnings were in line with expectations but the LBM win and high‑queue Medicare outlook add incremental upside.
Market effects
May signal broader adoption of LBM contracts in the diagnostics sector.
U.S. biotech and healthcare investors could see modest interest.
Limited to niche molecular diagnostics market.
Counterpoint
The modest revenue size and ongoing Medicare coverage uncertainty could limit upside.
Key entities
- CompanyLucid Diagnostics Inc.
NASDAQ‑listed molecular diagnostics firm.
- CompanyConcert
Laboratory benefit manager that signed a contract with Lucid.
- AnalystMark Massaro
BTIG analyst who upgraded Lucid and set a $2.50 price target.
